The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Why Did NGNE Stock Surge 25% In Pre-Market Today?